FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS

Dr Platzbecker discusses the FDA approval of luspatercept in lower-risk MDS with anemia; key efficacy and safety data from the COMMANDS trial; and how this approval addresses historically unmet needs for patients with MDS.